Background And Objective: To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in Japan and the United States.
Patients And Methods: Phase 2, multicenter, randomized, double-masked, 20-week studies (BAMBOO, Japan; CYPRESS, United States). Patients (n = 25 each study) received three monthly intravitreal injections of abicipar 1 mg or 2 mg or five monthly intravitreal injections of ranibizumab 0.5 mg.
Results: Mean best-corrected visual acuity change from baseline at week 16 (primary endpoint) for abicipar 1 mg, abicipar 2 mg, and ranibizumab was +7.8 letters, +8.9 letters, and +17.4 letters (BAMBOO); +4.4 letters, +10.1 letters, and +15.2 letters (CYPRESS). Mean central retinal thickness change from baseline was -187.3 μm, -196.5 μm, and -230.4 μm (BAMBOO); -106.5 μm, -112.8 μm, and -124.4 μm (CYPRESS). Uveitis or vitritis was reported in three abicipar-treated patients.
Conclusion: Abicipar demonstrated extended duration of effect and safety that were comparable between Japanese and non-Japanese patients with nAMD. Abicipar effectively treated Japanese patients with polypoidal choroidal vasculopathy. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e10-e22.].
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/23258160-20190129-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious.
Arch Soc Esp Oftalmol (Engl Ed)
July 2023
Clínica Oftalvist, Valencia, Spain.
The recent release of brolucizumab and the development of new antiangiogenic molecules as abicipar pegol has increased the interest towards inflammatory complications after intravitreal drug injection. Those drugs are associated to a higher rate of inflammatory adverse events compared to classic drugs. In this context it is essential to differentiate between sterile and infectious cases for a fast and effective treatment.
View Article and Find Full Text PDFImpact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.
Clin Ophthalmol
May 2023
Allergan plc, Irvine, CA, USA, at the time of this work.
Purpose: To evaluate the impact of modifying the abicipar pegol (abicipar) manufacturing process on the safety and treatment effect of abicipar in patients with neovascular age-related macular degeneration (nAMD).
Methods: A new process for manufacturing abicipar was developed to reduce host cell impurities. In a prospective, Phase 2, multicenter, open-label, 28-week clinical trial, patients (n=123) with active nAMD received intravitreal injections of abicipar 2 mg at baseline (day 1) and weeks 4, 8, 16, and 24.
[Modern trends in anti-VEGF therapy for age-related macular degeneration].
Vestn Oftalmol
May 2023
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Age-related macular degeneration (AMD) develops in people aged 50 years and older, its pathogenesis involves progressive destruction of the retinal pigment epithelium and Bruch's membrane. There are eight currently known anti-VEGF drugs for treating the neovascular form of AMD, four of them have already been registered and are used in clinical practice. The first registered drug was pegaptanib, which selectively blocks VEGF.
View Article and Find Full Text PDFNovel approach to antiangiogenic factors in age-related macular degeneration therapy.
Cent Eur J Immunol
February 2022
SPKSO Ophthalmic University Hospital, Warsaw, Poland.
Article Synopsis
- Age-related macular degeneration (AMD) is a leading cause of vision loss for those over 85, consisting of two types: neovascular and dry AMD.
- Neovascular AMD can result in irreversible vision damage if not treated, while dry AMD causes progressive atrophic changes in the macula.
- Recent advancements in treating neovascular AMD include photodynamic therapy and anti-VEGF agents, but dry AMD remains challenging, with new treatment approaches focusing on complement cascade inhibitors and targeted gene therapy.
Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs.
J Biol Chem
January 2022
Athebio AG, Zürich-Schlieren, Switzerland. Electronic address:
Designed ankyrin repeat proteins (DARPins) are antibody mimetics with high and mostly unexplored potential in drug development. By using in silico analysis and a rationally guided Ala scanning, we identified position 17 of the N-terminal capping repeat to play a key role in overall protein thermostability. The melting temperature of a DARPin domain with a single full-consensus internal repeat was increased by 8 °C to 10 °C when Asp17 was replaced by Leu, Val, Ile, Met, Ala, or Thr.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!